Many everyday choices mean weighing a benefit against a cost. A new phone is nice, but it leaves less money for groceries. Adults with ADHD (attention-deficit/hyperactivity disorder) often report trouble with this kind of trade-off. A trial from Norway, published in the journal Psychological Medicine, looked at how a common ADHD medicine, methylphenidate (sold as Ritalin, among other names), affects this balancing in a computer task. The main result: on the medicine, participants with ADHD paid more attention to costs, while their attention to rewards stayed the same.
What participants did
The team, led by psychologist Mads Lund Pedersen at the University of Oslo, tested 61 adults diagnosed with ADHD and 63 adults without it. First, people learned that each of six shapes was worth a certain number of points and that each of six colours took away a certain number. Then a coloured shape flashed on screen for a few seconds. They had to combine the two values quickly, then accept the offer if the total was positive or reject it if it was negative.
The participants with ADHD did the task twice: once after their usual dose of methylphenidate and once after a placebo, a dummy pill with no active ingredient. According to PsyPost's report, neither the participants nor the researchers knew which pill was given on which day. The comparison group also did the task twice, without any pill.
What the researchers found
On the placebo, the ADHD group made more mistakes than the comparison group. The researchers used a mathematical model that splits a quick decision into parts, such as how efficiently a person gathers information and how much information they wait for before answering. On placebo, the ADHD group took in information about both costs and benefits less efficiently, and answered on less information. People without ADHD gave costs more weight than benefits. The ADHD group on placebo showed the reverse.
On methylphenidate, the ADHD group processed cost information more efficiently, but their handling of rewards did not change. This moved their pattern closer to that of the comparison group. Among the participants with ADHD, those who reported more severe everyday symptoms were the least attentive to costs when they took the placebo.
What remains uncertain
This was a short lab task with points, not real decisions about money, driving or health. A better score on a screen does not show that real-life choices change. The authors also note other possible explanations. The medicine may have helped people remember the values they had learned, or do the mental subtraction, rather than changing how they weigh risks and rewards. People with severe additional mental health conditions were excluded, so the results may not apply to them. Some participants may have guessed when they had the real pill from how it felt, and that expectation could have affected their performance.
These are group averages from about 120 people. They do not predict how any one person will respond. The study describes how the medicine acted in one test. It does not offer guidance on treatment, and any questions about medication belong in a conversation with a prescriber.
